Open-label Extension Study of Brazikumab in Crohn's Disease
Public ClinicalTrials.gov record NCT03961815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE)
Study identification
- NCT ID
- NCT03961815
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Interventions
- Brazikumab Induction Dose Drug
- Brazikumab Maintenance Dose Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 5, 2020
- Primary completion
- Sep 18, 2023
- Completion
- Sep 18, 2023
- Last update posted
- Mar 31, 2026
2020 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 4
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Lincoln | California | 95648 | — |
| Research Site | Clearwater | Florida | 33756 | — |
| Research Site | Kissimmee | Florida | 34741 | — |
| Research Site | Lakeland | Florida | 33813 | — |
| Research Site | Miami | Florida | 33157 | — |
| Research Site | Miami | Florida | 33165 | — |
| Research Site | Miami Lakes | Florida | 33016 | — |
| Research Site | Tampa | Florida | 33626 | — |
| Research Site | Beachwood | Ohio | 44122 | — |
| Research Site | Houston | Texas | 77058 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03961815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03961815 live on ClinicalTrials.gov.